Tamoxifen (Tam), besides its action as an anti-estrogen, also inhibits cell proliferation of estrogen receptor (ER)-negative cancer cells by an unknown mechanism. In this study, we used ER-negative lung cancer cells to clarify such ER-independent inhibitory eect of Tam. We found that Tam induced G1 growth arrest in these cells. However, our results indicated that the expression of G1 cyclins (including D1, 2, 3 and E) was not regulated by Tam in these lung cancer cells. Additionally, the protein levels of G1 acting cyclin-dependent kinases (CDKs), CDK2, 4 and 6, was unaltered in Tam 
Tamoxifen (Tam), besides its action as an anti-estrogen, also inhibits cell proliferation of estrogen receptor (ER)-negative cancer cells by an unknown mechanism. In this study, we used ER-negative lung cancer cells to clarify such ER-independent inhibitory eect of Tam. We found that Tam induced G1 growth arrest in these cells. However, our results indicated that the expression of G1 cyclins (including D1, 2, 3 and E) was not regulated by Tam in these lung cancer cells. Additionally, the protein levels of G1 acting cyclin-dependent kinases (CDKs), CDK2, 4 and 6, was unaltered in Tam-treated lung cancer cells with the exception of CDK2 expression in H322 cells which was attenuated by Tam in a cell linespeci®c manner. We next examined the eect of Tam on the expression of cyclin-dependent kinase inhibitors (CDKIs) and our results demonstrated that the expression of p21 WAF1 and p27
KIP1
, but not p57
KIP2
, was strongly activated by Tam in these cells. The amounts of p21 WAF1 and p27 KIP1 co-immunoprecipitated with cyclin E were obviously increased after Tam treatment and reduced activity of cyclin E-associated kinases and accumulation of hypo-phosphorylated retinoblastoma (Rb) protein were clearly detected in Tam-incubated cells. No consentaneous induction of CDKIs was found when ER-negative lung cancer cells were incubated with cytotoxic drugs, cisplatin and etoposide, this indicates that enhancement of CDKI expression is not a non-speci®c eect of Tam. We also found that Tam may up-regulate p21 WAF1 expression via transcription activation. Considered together, these results suggest that Tam-induced growth inhibition in ER-negative lung cancer cells is associated with induction of p21 WAF1 and p27
KIP1
.
Keywords: tamoxifen; estrogen receptor; p21 WAF1 ; p27 KIP1 Tamoxifen (Tam), a synthetic anti-estrogen, is widely used for the treatment of breast cancer (Furr and Jordan, 1984; Jordan et al., 1991; Henderson et al., 1992) . This drug is thought to elicit its antiproliferation action by binding competitively to estrogen receptor (ER) and then blocking the mitogenic eect of estradiol (Sutherland et al., 1983; Jordan and Murphy, 1990) . Therefore, the response rate of ER-positive breast cancers to Tam is higher than that of ER-negative breast cancers (Jordan, 1994) . However, it was found that Tam also blocks cell growth of hormone-unresponsive breast cancer cells which do not express ER. Additionally, this drug was shown to be eective for a number of ER-negative tumors including lung cancer, brain cancer and melanoma (Croxtall et al., 1994; Couldwell et al., 1993; DelPrete et al., 1984) . This indicates that Tam, besides its action as an anti-estrogen, has eects on other critical components of intracellular signaling pathways. However, the molecular mechanism of such ER-independent growth inhibition is not known at present.
Recently, several potential targets for Tam have been identi®ed. First, Tam was demonstrated to inhibit protein kinase C (PKC) in a dose-dependent manner (O'Brian et al., 1986) . Since PKC plays a crucial role in the signaling pathway that promotes cell growth and transformation, it is possible that Tam may block cell proliferation by inhibiting PKC activity. Second, Tam may in¯uence cell growth by modulating the activity of phospholipases and the activation of lipid signaling pathways (Kiss, 1994) . Additionally, Tam was found to induce the expression of transforming growth factor-b (Knabbe et al., 1987) , to inhibit calmodulin dependent cyclin AMP phosphodiesterases (Rowlands et al., 1990) and to retard the metabolism of glycosphingolipids (Cabot et al., 1996) in dierent cell types. Whether these signaling molecules are involved in Tam-induced growth inhibition has not been clearly demonstrated.
Recent studies have indicated that the progression of cell cycle is governed by cyclins and cyclin-dependent kinases (CDKs) (Lew and Kornbluth, 1996) . The progression of cell cycle from G1 to S phase is controlled by D-and E-type cyclins and their major catalytic subunits CDK4, 6 and 2 (Pines, 1993; van den Heuvel and Harlow, 1993) . On the contrary, the progression of cell cycle through S, G2 and M is regulated by A-and B-type cyclins and CDK2 (Amon et al., 1993; Guadagno and Newport, 1996 INK4D ) which inhibits speci®cally the activity of cyclin D-associated kinases CDK4 and 6 (Serrano et al., 1993; Hirai et al., 1995) . The second class is the CIP/KIP family (including p21 WAF1 , p27 KIP1 and p57 KIP2 ) which has broad speci®city and inhibits the activity of most cyclin-CDK complexes (El-Deiry et al., 1993; Polyak et al., 1994) .
In this study, we try to elucidate the molecular mechanisms that mediate the growth-inhibitory eect of Tam in ER-negative cancer cells. We investigated the eect of Tam on the expression of cyclins, CDKs and CDKIs in human lung cancer cells which do not express ER and our results demonstrated that Tam induced the expression of p21 WAF1 and p27 KIP1 in these cells.
The expression of ER in human lung cancer cell lines used in this study was investigated by reverse transcription polymerase chain reaction (RT ± PCR) technique. As shown in Figure 1 , our results showed that H226, 322 and 358 lung cancer cells did not express ER. The failure of detection of ER expression in these cells is not due to the technical problems because we always included the ER-positive SKOV-3 human ovarian cancer cells as a positive control in our experiments to con®rm the results. An obvious DNA fragment of predicted length (345 bp) was observed in SKOV-3 cells, while this band was not found in these lung cancer cell lines. Additionally, the eciency of cDNA synthesis and PCR ampli®cation was checked by using a pair of primers designed to amplify the glyceraldehyde 3-phosphate dehydrogenase (G3PDH) gene fragments. As found in Figure 1 , a single band of 983 bp was detected in all samples tested and similar levels of this gene fragment were observed in all cell lines examined. Recently, a second type of ER, referred to as ERb, has been cloned. The appearance of this receptor has led to a revaluation of estrogen physiology and mechanisms of action of anti-estrogens (Kuiper et al., 1996; Tremblay et al., 1997) . We also examined the expression of ERb by using a pair of primers for the human ERb: TAGTGGTCCATCGC-CAGTTAT and GGGAGCCAACACTTCACCAT, corresponding to nucleotides 125-145 and 517-499 of ERb open reading frame (Enmark et al., 1997) to Figure 1 Detection of estrogen receptor (ER) expression by reverse transcription polymerase chain reaction (RT ± PCR). RT ± PCR was performed as described previously (Enmark et al., 1997) . Brie¯y, total RNA from SKOV-3, H226, 322 and 358 cells were extracted. First-strand cDNA was synthesized from 1 mg of total RNA by priming with oligo(dT) using a ®rst-strand cDNA synthesis kit (Clontech Laboratories, Palo Alto, CA, USA). The primer pair used for ER was AATTCAGATAATCGACGCCAG and GTGTTTCAACATTCTCCCTCCTC corresponding to nucleotides 457 ± 477 and 801 ± 779 of the human ER open reading frame. The primer pair predicts a 345 bp product. The primer pair for glyceraldehyde-3-phosphate dehydrogenase (G3PDH) is based on human sequence and this primer pair predicts a 983 bp fragment. One tenth of the cDNA synthesis was subjected to PCR ampli®cation by a DNA thermal cycler (Robocycler, Stratgene) using the following program: 958C 30 s, 336(958C 30 s, 568C 15 s, 728C 60 s), 728C 3 min. The PCR products were separated on a 2% agarose gel, stained with ethidium bromide and visualized under UV light. M: DNA size markers (Hung et al., 1996b) detect the expression of this ER in H226, 322 and 358 cells. We found that ERb was not expressed in these three cell lines (data not shown). Thus, the eect of Tam on these cells is independent of ER.
Subsequently, we examined whether Tam inhibited cell growth of these lung cancer cells. Cells were treated with dierent concentrations of Tam for 2 days and proliferation of these cells was evaluated by MTT assays (Mosmann et al., 1983) . We found that Tam suppressed cell growth in a dose-dependent manner in lung cancer cells (Figure 2a ). At the 10 mM concentration, Tam blocked 58, 48 and 40% of the growth of H226, 322 and 358 cells respectively. To further characterize the growth-inhibitory eect of Tam on these cells, we investigated cell cycle distribution of Tam-treated cells by¯ow cytometric analysis (Hung et al., 1996b) . As shown in Figure 2b , Tam induced cell cycle arrest at G1 phase in these lung cancer cells. Accumulation of cells in the G1 stage of the cell cycle was observed after continuous treatment with 10 mM Tam for 48 h. The percentages of cells at the G1 phase ranged from 34.5 ± 43.6% in untreated lung cancer cells. After Tam treatment, 55.2 ± 63.3% of cells accumulated in the G1 stage of the cell cycle. These results indicated that Tam blocked the progression of cell cycle from G1 to S phase.
Because G1 to S transition is controlled by G1 cyclins (D and E-type cyclins), we investigated the eect of Tam on the expression of cyclin D1, 2, 3 and E. Our results demonstrated that these cyclins were expressed in all three lung cancer cell lines (Figure 3a) . However, the expression of G1 cyclins was not regulated by Tam. We next investigated the eect of Tam on the expression of CDKs. Our data showed that the protein levels of CDK4 and 6 were not regulated by Tam (Figure 3a) . Similarly, the expression of CDK2 in H226 and 358 cells was unaltered after Tam treatment. However, we found that the protein level of CDK2 in H322 cells was reduced by Tam under same experimental conditions (Figure 3a ). CDKs were ®rst identi®ed as the catalytic subunits of the cyclin-CDK complexes and were originally thought to be constantly expressed during cell cycle progression. However, recent studies demonstrated that the expression of CDKs were regulated by external signals and CDK2 was found to be a target for retinoic acidmediated growth inhibition in human breast cancer cells (Teixeira and Pratt, 1997; Cover et al., 1998) . Since the inhibition of CDK2 expression by Tam was only observed in H322 cells, it is possible that this is a cell line-speci®c eect of Tam. At present, the Figure 3 Eect of Tam on the expression of G1 cyclins, CDKs and CDKIs in lung cancer cells. Cells were treated without or with 10 mM Tam for 48 h and were harvested by a lysis buer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 50 mM NaF, 0.5 mM sodium orthovanadate, 1 mg/ ml aprotinin, 1 mM phenylmethylsulfonyl¯uoride, 1 mg/ml leupeptin and 1 mg/ml pepstain (a). Protein concentrations of the cell lysates were determined by a DC protein assay kit (BioRad, Hercules, CA, USA). The cell lysates (20 mg protein/sample) were subjected to SDS-polyacrylamide gel electrophoresis (SDS ± PAGE) and immunoblotting analysis was performed as described previously (Hung et al., 1996a) . (a) The protein levels of G1 cyclins (including D1, 2, 3 and E) and G1 acting CDKs (including CDK2, 4 and 6) after Tam was investigated by Western blot analysis as described in Figure 3 Tamoxifen on CDKI induction T-H Lee et al molecular mechanism that mediates the inhibitory eect of Tam on CDK2 expression in H322 cells is unknown. We also investigated the kinetics of G1 cyclin and CDK expression in H358 cells, the protein levels of G1 cyclins (D1, 2 3 and E) and G1 acting CDKs (CDK2, 4 and 6) were not changed after incubation with Tam for dierent intervals ( Figure  3b ). We next examined whether Tam might activate CDKI expression to induce G1 growth arrest. Indeed, immunoblotting analysis revealed that Tam enhanced the expression of p21 WAF1 and p27 KIP1 . Conversely, the protein level of p57 KIP2 was low and was not aected by Tam in all these lung cancer cell lines (Figure 3c) . The weak signals of p57 KIP2 detected by immunoblotting are not due to the quality of the used antibody because we had included the whole cell lysates of Jurkat human leukemia cells as positive controls to con®rm the experimental results (data not shown). Since the major function of cyclin-CDK complexes is to phosphorylate the retinoblastoma protein (Rb) and to inactivate the growth-inhibitory action of this protein, we investigated the phosphorylation status of Rb in Tam-treated cells. As demonstrated in Figure 3c , most of the Rb protein in untreated cells appeared in the upper or hyper-phosphorylated form due to a reduced mobility of Rb phosphoproteins in SDS-polyacrylamide gel. After Tam treatment, Rb ran as a lower band indicative of the hypo-phosphorylated Rb proteins in drug-incubated cancer cells. Additionally, we performed kinetic analysis to study the eect of Tam on CDKI induction in H358 cells. As shown in Figure 3d , the expression of p21 WAF1 and p27 KIP1 was enhanced by Tam in a time-dependent manner and up-regulation of these two CDKIs was observed at 12 h after Tam addition. Furthermore, we included the SKOV-3 ovarian cancer cells in our study to examine the effect of Tam on ER-positive cells and our data, in accordance with the results of a previous study (Planas-Silva and Weinberg, 1997) , indicated that the expression of these CDKIs was not enhanced by Tam in these cells (Figure 3e) .
Because CDKIs were reported to inhibit the CDK activity by binding directly to the cyclin-CDK complexes, we examined the association of CDKIs (p21 WAF1 and p27
) and cyclin E-CDK2 complexes in Tam-treated lung cancer cells by using the immunoprecipitation/immunoblotting technique. We found that the amounts of p21 WAF1 and p27 KIP1 bound to cyclin E-CDK2 were increased by Tam (Figure 4 ). In addition, we studied the enzymatic activity of cyclin Eassociated kinases by in vitro kinase assays. The cyclin E-CDK complexes were immunoprecipitated with speci®c cyclin E antibody and the kinase activity of these complexes was determined by measuring the Figure 3 and protein concentrations of each sample were determined. 200 ml of cell lysates containing 300 mg of cellular proteins from control or Tam-incubated cells were immunoprecipitated with cyclin E antibody (Santa Cruz Biotech., Santa Cruz, CA, USA) at 48C for 4 h and immunocomplexes were collected by adding protein G agarose to the reaction mixtures at 48C for another 1 h. Agarose beads were pelleted brie¯y on a microcentrifuge and were washed three times with 1 ml lysis buer. Samples were subjected to SDS ± PAGE and the amounts of p21 WAF1 and p27 KIP1 protein co-immunoprecipitated with cyclin E were detected by Western blot analysis as described in Figure 3 . IP: immunoprecipitation. IB: immunoblotting. For in vitro kinase assays, the immunoprecipitates were washed three times with lysis buer and twice with kinase assay buer (20 mM Tris-HC1, pH 7.5, 5 mM MgC1 2 , 2.5 mM MnC1 2 and 1 mM dithiothreitol). Cyclin E-associated kinase activity was assessed by using histone H1 as kinase substrates as described previously (Planas-Silva and Weinberg, 1997) Figure 6 Transcriptional activation of the p21 WAF1 promoter by Tam in ER-negative H358 lung cancer cells. Cells were plated into 6-well plates at a density of 2610 5 cells/well and grown overnight. Cells were transfected with 2 mg of WWP-luc plasmids using 10 ml LipofectAMINE reagent (Life Technologies, Grand Island, NY, USA) in 1 ml of serum-and antibiotic-free DMEM/ F12 medium and were treated with dierent concentrations of Tam for 24 h. After incubation, cells were collected and assayed for luciferase activity using the luciferase assay system from Promega (Madison, WI, USA). The production of light was measured with a luminometer and luciferase activities were normalized for total protein concentrations. The relative light units per mg of protein were calculated as an average of three independent experiments of duplicate samples, and the error bars indicate the standard deviation amounts of radioactivity incorporated into the kinase substrate histone H1. As shown in Figure 4 , the enzymatic activity of cyclin E-CDK was attenuated by Tam in lung cancer cells. Considered together, these results suggest that Tam-induced p21  WAF1 and p27   KIP1 expression is associated with increase of cyclin/CDK/ CDKI complex formation, reduction of CDK activity, accumulation of hypo-phosphorylated Rb and G1 growth arrest in human lung cancer cells.
To test whether the induction of CDKIs is a speci®c eect of Tam, H226, 322 and 358 cells were treated with two cytotoxic drugs, cisplatin and etoposide (VP16), for 48 h and the expression of CDKIs was investigated. Our results demonstrated that although etoposide (5 mg/ml) activated p21 WAF1 expression in H358 cells, no similar eect was observed in H226 and 322 cells. Additionally, cisplatin at the concentration of 5 mg/ml did not aect the protein levels of p21 WAF1 in these cell lines. Our results also indicated that the expression of p27 KIP1 was not signi®cantly regulated by these two cytotoxic drugs. Therefore, induction of CDKIs is not a non-speci®c eect of Tam.
Another important question to be addressed is whether Tam activates p21 WAF1 and p27 KIP1 expression via transcription regulation. Because we did not have the p27
KIP1 promoter construct, we ®rst examined the eect of Tam on the promoter activity of p21 WAF1 by using the WWP-luc plasmid, a reporter plasmid in which the p21 WAF1 promoter region was inserted into a luciferase reporter construct (El-Deiry et al., 1993) in this study. H358 cells were plated into six-well plates at a density of 200 000 cells per well and grown overnight. Cells were transfected with 2 mg of the WWP-luc plasmid by using the LipofectAMINE technique and then incubated with dierent concentrations of Tam in DMEM/F12 medium containing 10% fetal calf serum for 24 h. After incubation, cells were lysed and the amount of luciferase activity was assayed by integrating total light emission over 10 s, using a luminometer. As demonstrated in Figure 6 , Tam activated p21 WAF1 expression in a dose-dependent manner and this drug at 10 mM induced an average 3.2-fold increase of luciferase activity in H358 cells. These results suggest that Tam may induce p21 WAF1 expression via transcription activation.
A very recent study demonstrated that inhibition of human pancreatic cancer cell growth by Tam is associated with an increase of p21 WAF1 mRNA expression (Robinson et al., 1998) . However, the expression status of ER was not clari®ed in their study. When this manuscript was ®rst submitted for reviewing, another report showed that prostate cancer cell growth inhibition by Tam is linked with inhibition of PKC and induction of p21 WAF1 (Rohl et al., 1998) . Similarly, direct analysis of ER-a and -b was not performed in their work, although lack of the classic ER (ER-a) in one of the used cell lines PC3-M has been reported in a separate study (Kyle et al., 1997 (Planas-Silva and Weinberg, 1997) . Indeed, we also found that CDKI expression was not regulated by Tam in ER-positive SKOV-3 ovarian cancer cells. Thus, Tam may inhibit cell proliferation in ER-positive and -negative cells by dierent mechanisms. Second, the induction of CDKIs by Tam may occur in the absence of p53. Accumulating evidences suggest that p53, a tumor suppressor gene, plays a central role in the induction of p21 WAF1 in normal cells (Bates and Vousden, 1996) . However, recent studies demonstrated that genetic defect of the p53 gene have been detected in approximately 45% of primary lung tumors (Takahashi et al., 1989; Chiba et al., 1990) . Furthermore, more than 70% of non-small cell lung cancer (NSCLC) cell lines had mutations of the p53 gene (Mitsudomi et al., 1992) . The p53 gene in H226, 322 and 358 cells was reported to be inactivated by point mutation or deletion (Mitsudomi et al., 1992; Takahashi et al., 1989) . Therefore, enhancement of p21 WAF1 by Tam is not dependent on p53 in these cell lines. We are now mapping the critical elements in the p21 WAF1 promoter region that mediate the stimulatory eect of Tam on the expression of this CDKI. The regulation of p27 KIP1 is still poorly understood. The expression of this CDKI has been reported to be controlled by a post-translational mechanism (Hengst and Reed, 1996; Pagano et al., 1995) . However, recent reports indicated that transcription of the p27 KIP1 gene was modulated by several dierentiation-inducing drugs (Liu et al., 1996; Poluha et al., 1996) . Cloning of the promoter region of the human p27 KIP1 revealed that several crucial regulatory elements was found in this region including Sp1, NF-kB, Ap2 and CTF, but not p53, sites (Minami et al., 1997) . Therefore, induction of p27 KIP1 is also not dependent on p53. Construction of plasmids containing dierent deletions of the p21 WAF1 and p27 KIP1 promoter regions for future promoter activity assays will be helpful for the elucidation of the critical binding motifs that involved in the regulation of expressions of these two CDKIs by Tam. Recent studies indicated that p21 WAF1 expression was a predictor for favorable prognosis for NSCLC patients (Komiya et al., 1997; Caputi et al., 1998; Bennett et al., 1998) . Additionally, another work has indicated that more than 70% of NSCLC tumors showed reduced p27 KIP1 immunoreactivity and the expression of this CDKI was found to be a favorable prognostic factor for patient survival (Yatabe et al., 1998) . It should be noted that the concentration of Tam used in this study can be attained in serum with high-dose Tam therapy (Trump et al., 1992; McClay et al., 1997) . Collectively, these ®ndings indicate that Tam is a potent inducer of CDKI expression and an eective inhibitor of cell growth in NSCLC cells in vitro and this drug warrants further in vivo study.
